Comparing Prednisone and Methotrexate to Off-label Biologic Infliximab for Management of Ocular Uveitis: A Cost-minimization Analysis

Background: Approximately 3.75% of cases of blindness in the United States are caused by uveitis. Incurred clinical costs and lost productivity related to vision loss in these cases totals $3.58 billion annually. Objective: To evaluate whether infliximab, a modern off-label biologic, is cost-effecti...

Descripción completa

Detalles Bibliográficos
Autores principales: Padula, William V., Cordero-Coma, Miguel, Yilmaz, Taygan, Gallagher, Michéal J., Campbell, Jonathan D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Columbia Data Analytics, LLC 2015
Materias:
Ophthalmology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10471400/
https://www.ncbi.nlm.nih.gov/pubmed/37663586
http://dx.doi.org/10.36469/9895

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10471400/
https://www.ncbi.nlm.nih.gov/pubmed/37663586
http://dx.doi.org/10.36469/9895

Ejemplares similares